Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · GWAS Meta-Analysis: Mood Disorders

Bipolar and Major Depressive Disorder: A Meta-Analysis of Genome-Wide Association Study (GWAS) Data

Genome-wide association meta-analyses have repeatedly found that bipolar disorder and major depressive disorder share part of their genetic architecture. This article examines what the published data show and identifies where secondary summaries overstate the findings.

Pubrica AcademyWritten by a genetics and bioinformatics research writer Reviewed bya psychiatric genomics reviewer Published10 October 2026 Last checked10 October 2026 Reading time7 minutes Sources10 peer-reviewed

Bipolar disorder and major depressive disorder (MDD) are diagnosed as distinct conditions, although clinicians have long observed overlapping symptoms, familial patterns and treatment responses. Genome-wide association studies (GWAS) provided the first direct molecular means of investigating whether that overlap has a genetic basis, through meta-analysis of association data across large patient cohorts. The published results are informative, but the genetic overlap they report is more specific and more qualified than many secondary summaries suggest.

Learning objectives

  • What a genome-wide association meta-analysis measures, and what it does not
  • The published evidence on shared genetic risk between bipolar disorder and MDD
  • The magnitude of that overlap relative to other psychiatric disorder pairs in the same large-scale studies
  • The reasons genetic correlation findings do not translate directly into diagnostic practice

Common misconceptions

  • “A GWAS meta-analysis finding genetic overlap means bipolar disorder and MDD are the same underlying disease.” Large consortium studies describe a genetic correlation or shared risk-variant overlap between the two conditions, not identity. The same body of research found an even stronger genetic similarity between schizophrenia and bipolar disorder, while still treating all these conditions as clinically distinct diagnoses.
  • “Any single psychiatric GWAS paper settles which genes 'cause' bipolar disorder or depression.” Early meta-analyses, such as the 2011 Wellcome Trust Case-Control Consortium-linked study in Molecular Psychiatry, were concise, targeted syntheses of existing datasets seeking shared signal rather than exhaustive gene discovery exercises; subsequent, much larger consortium efforts refined and extended those early findings.

The hypotheses tested by a GWAS meta-analysis

A genome-wide association study scans the genome for single nucleotide polymorphisms (SNPs) statistically associated with a trait or disorder in a given sample. A meta-analysis combines the summary statistics from multiple independent GWAS datasets to increase statistical power and to detect signal that no single study was large enough to identify reliably. When applied across two different psychiatric diagnoses, the aim is specifically to determine whether the same genetic variants that raise risk for one disorder also raise risk for the other; this is a question about shared genetic architecture, not about diagnostic equivalence.

An early meta-analysis of combined bipolar disorder and MDD data

One of the earlier published efforts to combine GWAS data directly across these two mood disorders is Liu et al., “Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder,” published in Molecular Psychiatry in 2011, with contributions from the Wellcome Trust Case-Control Consortium and a large international author group 1. The study’s subject matter, reflected in its indexed keywords, centred on genome-wide association signal relevant to both disorders, including loci in genes coding for L-type calcium channels, a class of genes that has recurred across multiple independent psychiatric genetics studies as a candidate shared-risk pathway 1.

Subsequent large-scale cross-disorder findings

A substantially larger analysis was undertaken by the Cross-Disorder Group of the Psychiatric Genomics Consortium, which published “Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs” in Nature Genetics in 2013. That study combined data from more than 75,000 individuals, comparing roughly one million genetic variants across five disorders: schizophrenia, bipolar disorder, major depression, autism and attention-deficit/hyperactivity disorder 2. The results showed that schizophrenia and bipolar disorder shared the strongest genetic similarity of the pairs studied; bipolar disorder and major depression showed a significant, if less pronounced, genetic overlap; schizophrenia and major depression also overlapped; and bipolar disorder and ADHD showed a weaker but still detectable shared signal 2.

The consortium’s own interpretation was notably cautious about diagnostic implications: the overlapping findings led researchers to suggest that the biological causes of these conditions may be more similar than the current categorical diagnostic system implies, rather than to claim that any two disorders are genetically identical 2.

Interpretation of genetic overlap studies

Two principles apply to researchers citing this literature. First, authors should be precise about which study is cited and what scale of data it analysed; an early, narrowly targeted meta-analysis is not interchangeable with a later consortium effort spanning tens of thousands of individuals and multiple disorders. Second, authors should avoid translating “genetic overlap” or “genetic correlation” into claims about diagnosis, treatment interchangeability or disease identity; the published consortium work itself stops at describing shared genetic risk architecture and does not recommend any change to clinical diagnostic categories.

Findings of the largest current bipolar disorder GWAS

The 2011 and 2013 studies described above have since been superseded by much larger consortium efforts, and an accurate account of the current evidence requires citing these newer analyses directly rather than only their smaller predecessors. The third wave of the Psychiatric Genomics Consortium’s bipolar disorder GWAS, published in Nature Genetics in 2021, analyzed 41,917 bipolar disorder cases and 371,549 controls of European ancestry and identified 64 associated genomic loci, more than quadruple the number found in earlier PGC bipolar analyses3. Integration of gene-expression data identified 15 genes with a credible biological link to bipolar disorder, including several (HTR6, MCHR1, DCLK3 and FURIN) that the authors identify as existing or plausible drug targets, thereby providing concrete candidates for future mechanistic and treatment research rather than only a map of statistical associations3.

Findings of the largest current depression GWAS

With respect to major depressive disorder, a 2019 meta-analysis in Nature Neuroscience combined the three largest available depression GWAS datasets into a discovery sample of 807,553 individuals (246,363 cases and 561,190 controls) and identified 102 independent genetic variants associated with depression, linked to 269 genes4. Eighty-seven of those 102 variants remained statistically significant after correction for multiple testing in an independent replication sample of more than 1.3 million individuals, providing a far larger and more robust evidentiary base than the original 2011 bipolar-MDD meta-analysis could offer4. The study’s principal finding, that associated genes were enriched in prefrontal brain regions, also provided the first genome-wide-scale anatomical indication of where the genetic risk for depression is most biologically active.

Three genetic clusters in the 2019 eight-disorder analysis

A 2019 analysis in Cell by the Cross-Disorder Group of the Psychiatric Genomics Consortium extended the cross-disorder comparison described earlier in this article from five to eight psychiatric disorders and refined its conclusion considerably5. Rather than describing a single undifferentiated pattern of genetic overlap, the study’s genetic correlation analysis identified three distinguishable groups of inter-related disorders: broadly, a group centred on compulsive and anxiety-related conditions, a group centred on mood and psychotic disorders (which includes bipolar disorder and major depression, alongside schizophrenia), and a group centred on early-onset neurodevelopmental conditions5. This three-cluster structure provides a more precise and more recent description of the genetic overlap between bipolar disorder and major depression than the single pairwise comparison typically quoted from the 2013 study.

A separate, dedicated comparison published in Biological Psychiatry in 2020, which explicitly combined bipolar disorder and major depressive disorder GWAS data into a single “mood disorder” meta-analysis spanning more than 185,000 cases and 439,000 controls, reported a genetic correlation of 0.55 between this combined mood-disorder phenotype and the Psychiatric Genomics Consortium’s bipolar disorder GWAS specifically, alongside SNP-based heritability estimates of approximately 9% for major depression and 17-23% for bipolar disorder6. This figure of 0.55 is one of the more precise and recent quantitative estimates available of the degree to which the genetic architectures of these two disorders overlap: a moderate correlation, well short of genetic identity.

Genetic differentiation of bipolar disorder and MDD

Most of the literature described above is designed to detect overlap. A 2024 study published in the British Journal of Psychiatry inverted the question, constructing a genome-wide association analysis specifically designed to maximize the genetic contrast between bipolar disorder cases and major depression cases, rather than their overlap with shared controls7. This “BD-vs-MDD” phenotype correlated strongly with the standard PGC bipolar disorder GWAS (genetic correlation of 0.95) but showed essentially no correlation with the standard PGC major depression GWAS (genetic correlation of −0.05, a value statistically indistinguishable from zero)7. The authors also found a modestly stronger genetic association between this BD-vs-MDD contrast and genetic risk for alcohol use than existed for standard bipolar disorder risk alone, and proposed, cautiously, the hypothesis that alcohol-related genetic risk could contribute independently to the progression of depression to a bipolar presentation in some patients7. Taken together, this study and the shared-risk literature indicate that bipolar disorder and major depression are neither fully distinct nor interchangeable at the genetic level: they overlap substantially in aggregate genetic risk while remaining clearly separable along specific genetic dimensions that a well-designed contrastive GWAS can isolate.

Key points

Key points

Published GWAS meta-analyses indicate a substantive but partial genetic overlap between bipolar disorder and major depressive disorder, smaller than the overlap between schizophrenia and bipolar disorder, without implying that the conditions constitute the same disease.

Practical application

Practical application

  1. Cite the specific study rather than the general claim. Early targeted meta-analyses and later large consortium cross-disorder studies do not constitute interchangeable evidence.
  2. State the sample scale explicitly. Report cohort size and the number of disorders or variants compared when describing genetic overlap findings.
  3. Distinguish genetic correlation from diagnosis. Report shared genetic risk as evidence at the level of genetic architecture rather than as a basis for merging clinical diagnoses.
  4. Distinguish qualitative from quantitative findings. State clearly when a cited source reports overlap qualitatively (for example, ‘strongest’ or ‘weaker’) rather than as a precise correlation coefficient.

Frequently asked questions

Published GWAS meta-analyses report a genuine but partial genetic overlap between the two, smaller than the overlap found between schizophrenia and bipolar disorder in the same body of research.

It analysed genome-wide SNP data from more than 75,000 individuals across five psychiatric disorders: schizophrenia, bipolar disorder, major depression, autism and ADHD.

The researchers raised that possibility as a hypothesis for future classification work, but the published findings themselves describe shared genetic architecture, not a diagnostic reclassification.

References

  1. Liu D, Craddock N, O'Donovan MC, Owen MJ, et al. Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder. Molecular Psychiatry. 2011;16(1):2-4. read 10 October 2026. View source
  2. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics. 2013. read 10 October 2026. View source
  3. Mullins N, Forstner AJ, O'Connell KS, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics. 2021;53:817-829. read 10 October 2026. View source
  4. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience. 2019;22(3):343-352. read 10 October 2026. View source
  5. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179(7):1469-1482.e11. read 10 October 2026. View source
  6. Bipolar Disorder Working Group of the PGC & Major Depressive Disorder Working Group of the PGC. The genetics of the mood disorder spectrum: genome-wide association analyses of more than 185,000 cases and 439,000 controls. Biological Psychiatry. 2020. read 10 October 2026. View source
  7. A genome-wide association study designed to maximize the genetic contrast between bipolar disorder and major depressive disorder, published in the British Journal of Psychiatry (2024), reporting genetic correlations of the resulting phenotype with the standard PGC bipolar disorder and PGC major depression GWAS. read 10 October 2026. View source
  8. GWAS Catalog (EMBL-EBI / NHGRI). Curated catalog of published genome-wide association studies, including the bipolar disorder and major depressive disorder GWAS discussed above. read 10 October 2026. View source
  9. Psychiatric Genomics Consortium. Overview of PGC working groups, including the Bipolar Disorder and Major Depressive Disorder Working Groups whose summary statistics underlie the studies cited in this article. read 10 October 2026. View source
  10. National Institute of Mental Health. Genetics and mental illness: an overview of how genome-wide association studies are used to study shared and distinct genetic risk across psychiatric disorders. read 10 October 2026. View source

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Bipolar and Major Depressive Disorder: A Meta-Analysis of Genome-Wide Association Study (GWAS) Data. Pubrica. https://pubrica.com/academy/meta-analysis/bipolar-and-major-depressive-disorder-a-meta-analysis-of-biotechnology-genome-wide-association-data/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

GWAS citation checklist

This checklist is intended for use before citing genetic-overlap findings in psychiatric genomics.

[ ] Specific study and year identified (not a general claim)
[ ] Sample size and number of disorders/variants noted
[ ] Genetic overlap reported as architecture-level, not diagnostic
[ ] Qualitative vs. quantitative overlap distinguished
[ ] Later, larger consortium data checked against earlier findings

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s data analytics team verifies the genomic studies to which a manuscript’s genetic overlap claims refer, and checks that sample scale and findings are represented accurately.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Reporting GWAS and genetic overlap findings in bipolar disorder and depression research

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.